Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 5/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorescin SCHEMBL31164674 | 1.00 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL31164673 | 1.00 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL27403 | 1.00 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL31214151 | 1.00 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL1507667 | 0.98 | CYP2C9 (0.69) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL1938032 | 0.98 | CYP2C9 (0.69) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL5579981 | 0.94 | CYP2C9 (0.64) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL4342272 | 0.94 | CYP2C9 (0.64) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL7807189 | 0.94 | CYP2C9 (0.64) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL6036317 | 0.93 | CYP2C9 (0.62) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715466-B1 | METHOD FOR IN VIVO EVALUATION OF BIOLUMINESCENCE | CALIPER LIFE SCIENCES INC (US) | 2025-05-07 | — | — | EP | claimed |
| CN-114080225-A | Methods of treating cancer | 来凯有限公司 | 2022-02-22 | — | — | CN | claimed |
| US-12629424-B2 | Targeting Pleckstrin-2 for treating cancer | NORTHWESTERN UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-12589032-B2 | Opthalmological imaging and laser delivery device, system and methods | PULSEMEDICA CORP. (CA) | 2026-03-31 | — | — | US | disclosed |
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2026-02-12 | — | — | US | disclosed |
| US-12487237-B2 | Methods and devices for detection of biological materials using electric field assisted rapid analyte capture | UNIVERSITY OF WYOMING (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2025235781-A1 | SINGLE COLOR FLUORESCENT OPTICAL SYSTEMS | ELEMENT BIOSCIENCES, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12406919-B2 | Stack of horizontally extending and vertically overlapping features, methods of forming circuitry components, and methods of forming an array of memory cells | MICRON TECHNOLOGY, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250262091-A1 | OPTHALMOLOGICAL IMAGING AND LASER DELIVERY DEVICE, SYSTEM AND METHODS | PULSEMEDICA CORP. (CA) | 2025-08-21 | — | — | US | disclosed |
| US-20250236667-A1 | ANTIBODIES TO MUTANT CALRETICULIN AND USES THEREOF | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (AU) | 2025-07-24 | — | — | US | disclosed |
| US-20250223631-A1 | METHODS AND KITS FOR DETECTION OF TARGETS USING PCR AND PADLOCK PROBES | APLEX BIO AB (SE) | 2025-07-10 | — | — | US | disclosed |
| US-11276733-B2 | Arrays of memory cells and methods of forming an array of vertically stacked tiers of memory cells | MICRON TECHNOLOGY, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274332-B2 | Methods of administering 3,4-diaminopyridine | SERB SA (BE) | 2022-03-15 | — | — | US | disclosed |
| US-11268128-B2 | Methods of administering 3,4-diaminopyridine | SERB SA (BE) | 2022-03-08 | — | — | US | disclosed |
| WO-2022045398-A1 | ULTRASOUND-GUIDED DRUG DELIVERY SYSTEM USING ULTRASOUND CONTRAST MEDIUM CONTAINING LIGAND HAVING DRUG IMMOBILIZED THERETO THROUGH ESTER BOND | 삼육대학교산학협력단 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022040484-A1 | DIAGNOSTIC METHODS AND COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-114080225-A | Methods of treating cancer | 来凯有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20220042068-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2022-02-10 | — | — | US | disclosed |
| US-20220033876-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2022-02-03 | — | — | US | disclosed |
| US-20220033877-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589032-B2 | Opthalmological imaging and laser delivery device, system and methods | HCRTR2, LOXL2, SPOP | CYP2C9 3067/4885ALDH1A1 4589/4885HSD17B10 3350/4885 |
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, SAT1, NANS | CYP2C9 589/4885ALDH1A1 684/4885HSD17B10 4062/4885 |
| US-12629424-B2 | Targeting Pleckstrin-2 for treating cancer | PLEKHA1, PLEKHG3, PLEC | CYP2C9 4830/4885ALDH1A1 4187/4885HSD17B10 2047/4885 |
| US-20220033876-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, NAT10, SAT1 | CYP2C9 652/4885ALDH1A1 388/4885HSD17B10 1813/4885 |
| US-11274332-B2 | Methods of administering 3,4-diaminopyridine | NAT1, NAT10, SAT1 | CYP2C9 652/4885ALDH1A1 388/4885HSD17B10 1813/4885 |
| US-11268128-B2 | Methods of administering 3,4-diaminopyridine | NAT1, NAT10, SAT1 | CYP2C9 652/4885ALDH1A1 388/4885HSD17B10 1813/4885 |
| US-20220033877-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, NAT10, SAT1 | CYP2C9 652/4885ALDH1A1 388/4885HSD17B10 1813/4885 |
| US-20220042068-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, NAT10, SAT1 | CYP2C9 652/4885ALDH1A1 388/4885HSD17B10 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.